NCIt definition : A preparation of autologous blood T-lymphocytes that have been genetically modified
to express a chimeric antigen receptor (CAR) consisting of an anti-CD20 scFv (single
chain variable fragment); the cytoplasmic portion of the human TCR-[zeta] molecule;
and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and
antineoplastic activities. Upon transfusion, anti-CD20-CAR-CD3zeta-4-1BB-expressing
autologous T-lymphocyte cells direct T-cells to CD20-expressing tumor cells. This
results in cytotoxic T lymphocyte (CTL) and antibody responses against CD20-expressing
tumor cells, causing tumor cell lysis. The CD20 antigen, a non-glycosylated cell surface
phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage
malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the
T-cell receptor (TCR)/CD3 complex and regulates the assembly of complete TCR complexes
and their expression on the cell surface. The 4-1BB co-stimulatory molecule signaling
domain enhances activation and signaling after recognition of CD20; the inclusion
of this signaling domain may increase the antitumor activity compared to the inclusion
of the CD3-zeta chain alone.;